GR Receptor as Target for Therapeutic Drugs (P11219)

Target Name: Kainate Receptor (GluR)

NCBI ID: P11219

Kainate Receptor (GluR)

Other Name(s): iGluR | Ionotropic Kainate Receptor | Glu-R

GR Receptor as Target for Therapeutic Drugs

The Kainate Receptor (GR) is a protein that is expressed in various tissues throughout the body, including the brain, nervous system, and endocrine system. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a crucial role in cellular signaling. The GR is involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and hormone regulation.

The GR is a key receptor for several classes of drugs, including muscle relaxants, sensory depressants, and neurotransmitter antagonists. It is also a potential drug target for several diseases, including anxiety, depression, and neurodegenerative disorders.

Despite the importance of the GR in cellular signaling, its biology remains relatively well understood. The GR is a non-spinalGPCR, which means that it is not localized to a specific spinal cord region. It is also a nonspecific subtype of the GR, which means that it is not specific for any particular signaling pathway.

IgGURAs

IgGURAs (Immunoglobulin G-Unconjugated Activating Receptors) are a type of surface protein that is expressed in various tissues, including the brain, nervous system, and endocrine system. They are composed of a monoclonal antibody (mAb) that is specific for a particular protein, and they are involved in cellular signaling.

IgGURAs have been identified as potential drug targets for several diseases, including neurodegenerative disorders, autoimmune diseases, and psychiatric disorders. They are also a potential biomarker for certain diseases, such as cancer.

The Kainate Receptor is a type of IgGURA that is expressed in various tissues throughout the body, including the brain, nervous system, and endocrine system. It is involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and hormone regulation.

The GR is a key receptor for several classes of drugs, including muscle relaxants, sensory depressants, and neurotransmitter antagonists. It is also a potential drug target for several diseases, including anxiety, depression, and neurodegenerative disorders.

Targeting the GR

The GR is a potential drug target for several diseases, including anxiety, depression, and neurodegenerative disorders. Drugs that have been shown to target the GR include:

1. Atogepant: Atogepant is a selectiveGR antagonist that is used to treat anxiety disorders. It works by blocking theGR and reducing the release of neurotransmitters, such as dopamine, in the brain.
2. Ubrogepant: Ubrogepant is anotherGR antagonist that is used to treat anxiety disorders. It works by blocking theGR and reducing the release of neurotransmitters, such as dopamine, in the brain.
3. Naltrexone: Naltrexone is aGR antagonist that is used to treat anxiety disorders. It works by blocking theGR and reducing the release of neurotransmitters, such as dopamine, in the brain.
4. Ketamine: Ketamine is anGR agonist that is used to treat depression and some other psychiatric disorders. It works by increasing the release of neurotransmitters, such as serotonin and dopamine, in the brain.

5

Protein Name: Kainate Receptor (GluR) (nonspecified Subtype)

The "Kainate Receptor (GluR) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Kainate Receptor (GluR) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets